Diligence memo · auto-generated · as of July 2, 2026
TAUC3 Biologics Ltd
TAUC3 Biologics Ltd looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
TAUC3 Biologics Ltd operates in Biotechnology, based in London.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
TAUC3 Biologics Ltd has raised $839K in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Pre-Seed (a round under $1.0M).
Largest single filing: $690K on 2022-01-24.
Most recent recorded round closed around 2022-01-24.
Valuation (modeled)modeled
Provath models TAUC3 Biologics Ltd at approximately $14M (range $368K–$102M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 4.48× the median modeled value of Pre-Seed Biotechnology companies in 2022–2024 (185 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 15 months.
Last raise 4.4 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 4.6× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 16% of Biotechnology peers (4293 compared).
Modeled value ranks above 24% of those peers.
Closest niche peers: TissueMill Technologies LLC, Aldebaran Therapeutics, Inc., BullFrog AI Holdings, Inc., Vesicle Therapeutics Inc., UCHU Biosensors, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.